米非司酮对人类围植入期子宫内膜整合素表达的影响  被引量:3

Effects of a Single and Low Dose of Mifepristone on Integrin Expression in Human Endometrium During the Peri-implantation Period

在线阅读下载全文

作  者:武捷[1] 王介东 王龙生[1] 朱蓬弟 程捷 

机构地区:[1]西安交通大学医学院组织学与胚胎学教研室,西安710061 [2]国家计划生育委员会科学技术研究所,北京100081

出  处:《生殖与避孕》2003年第1期22-25,T004,共5页Reproduction and Contraception

基  金:世界卫生组织(WHO)资助

摘  要:目的:观察具有正常生育能力的妇女服用米非司酮后对围植入期子宫内膜整合素表达的影响,以探讨小剂量米非司酮用于紧急避孕可能的作用机制。方法:以具有正常生育能力的健康妇女为研究对象。11名自愿受试者随机分为两组:LH—2组(n=5)和LH+2组(n=6),于对照周期和实验周期分别在LH—2或LH+2一次性口服安慰剂和米非司酮10 mg,在两个周期的LH+7各取一次子宫内膜,利用免疫组化技术,研究每位受试者用药前后子宫内膜整合素α_1、α_4、β_3亚基表达的改变。结果:LH—2组于用药后整合素α_1、α_4亚基在子宫内膜腺上皮的表达增强,而LH+2组于用药前后无显著差异。两组整合素β_3亚基的着色于用药前后均无显著差异。结论:米非司酮干扰了整合素在“植入窗”内的正常表达,提示米非司酮的避孕效果在于损伤了子宫内膜的感受态。Objective:In order to gain further knowledge about the mechanism of emergency contraception, during the peri-implantation period the effect of single and low dose of Mifepristone on the expression of inte-grin level in endometrium of healthy women were observed. Methods: Eleven healthy women with proven fertility were randomly divided into two groups; group LH-2(n=5) and LH + 2(n = 6). During the control and treatment cycle, placebo or 10 mg Mifepristone were given orally to group LH-2 on cycle day LH - 2 cr to group LH+2 on cycle day LH+2, respectively. Endometrial tissue specimen was obtained from each women during both the control and the treatment cycle on cycle day LH + 7 and was assessed by immunohistochemical analysis to measure the change of integrin α1, α4, β3 subunit expression on the endometrium after Mifepristone using. Results: Mifepristone significantly increased the expression of α1,α4 subunit in glandular epithelium only in group LH-2. The expression of β3 integrin subunit remain all the same in both groups. Conclusion:Our study demonstrates that treatment with Mifepristone interferes with integrin distribution during the implantation window, which may imply that the contraceptive effect of Mifepristone is primarily due to impaired endometrial receptivity.

关 键 词:米非司酮 围植入期 子宫内膜 整合素 

分 类 号:R965[医药卫生—药理学]

 

参考文献:

正在载入数据...

 

二级参考文献:

正在载入数据...

 

耦合文献:

正在载入数据...

 

引证文献:

正在载入数据...

 

二级引证文献:

正在载入数据...

 

同被引文献:

正在载入数据...

 

相关期刊文献:

正在载入数据...

相关的主题
相关的作者对象
相关的机构对象